An IgM antibody targeting the receptor binding site of influenza B blocks viral infection with great breadth and potency.

Abstract

Broadly neutralizing antibodies (bnAbs) targeting the receptor binding site (RBS) of hemagglutinin (HA) have potential for developing into powerful anti-influenza agents. Several previously reported influenza B bnAbs are nevertheless unable to neutralize a portion of influenza B virus variants. HA-specific bnAbs with hemagglutination inhibition (HI) activity may possess the ability to block virus entry directly. Polymeric IgM antibodies are expected to more effectively inhibit virus attachment and entry into target cells due to their higher avidity and/or steric hindrance. We therefore hypothesized that certain RBS-targeted IgM antibodies with strong cross-lineage HI activity might display broader and more potent antiviral activity against rapidly evolving influenza B viruses. Methods: In this study, we generated IgM and IgG bnAbs targeting the RBS of influenza B virus using the murine hybridoma technique. IgM and IgG versions of the same antibodies were then developed by isotype switching and characterized in subsequent in vitro and in vivo experiments. Results: Two IgM and two IgG bnAbs against influenza B virus HA were identified. Of these, one IgM subtype antibody, C7G6-IgM, showed strong HI and neutralization activities against all 20 representative influenza B strains tested, with higher potency and broader breadth of anti-influenza activity in vitro than the IgG subtype variant of itself, or other previously-reported influenza B bnAbs. Furthermore, C7G6-IgM conferred excellent cross-protection against distinct lineages of influenza B viruses in mice and ferrets, performing better than the anti-influenza drug oseltamivir, and showed an additive antiviral effect when administered in combination with oseltamivir. Mechanistically, C7G6-IgM potently inhibits infection with influenza B virus strains from different lineages by blocking viral entry. Conclusion: In summary, our study highlights the potential of IgM subtype antibodies in combatting pathogenic microbes. Moreover, C7G6-IgM is a promising candidate for the development of prophylactics or therapeutics against influenza B infection.

• Authors: Chenguang Shen, Minwei Zhang, Yuanzhi Chen, Limin Zhang, Guosong Wang, Junyu Chen, Siyuan Chen, Zizhen Li, Feixue Wei, Jing Chen, Kunyu Yang, Shuxin Guo, Yujing Wang, Qingbing Zheng, Hai Yu, Wenxin Luo, Jun Zhang, Honglin Chen, Yixin Chen, Ningshao Xia
• Journal: Theranostics (Theranostics) Vol. 9 Issue 1 Pg. 210-231 ( 2019) ISSN: 1838-7640 [Electronic] Australia
• PMID: 30662563 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't)

Chemical References

• Antibodies, Monoclonal
• Antibodies, Neutralizing
• Antibodies, Viral
• Hemagglutinin Glycoproteins, Influenza Virus
• Immunoglobulin G
• Immunoglobulin M

Topics

• Animals
• Antibodies, Monoclonal (administration & dosage, immunology, isolation & purification)
• Antibodies, Neutralizing (administration & dosage, immunology)
• Antibodies, Viral (administration & dosage, immunology)
• Binding Sites (immunology)
• Disease Models, Animal
• Enzyme-Linked Immunosorbent Assay
• Hemagglutination Inhibition Tests
• Hemagglutinin Glycoproteins, Influenza Virus (immunology)
• Immunization, Passive (methods)
• Immunoglobulin G (administration & dosage, immunology, isolation & purification)
• Immunoglobulin M (administration & dosage, immunology, isolation & purification)
• Influenza B virus (growth & development, immunology)
• Mice, Inbred BALB C
• Neutralization Tests
• Orthomyxoviridae Infections (prevention & control, therapy)
• Treatment Outcome